Table 3.
Surface under the cumulative ranking curve (SUCRA) results for outcomes.
| Treatment | 6MWD change | mPAP change | WHO FC improvement | Clinical Worsening | death | AEs | SAEs |
|---|---|---|---|---|---|---|---|
| Bosentan + Sildenafil | 0.990 | 0.844 | 0.464 | 0.484 | 0.570 | 0.844 | 0.444 |
| Sildenafil | 0.875 | 0.321 | 0.601 | 0.536 | 0.419 | 0.773 | 0.117 |
| Bosentan + Iloprost | 0.823 | 0.959 | 0.948 | 0.850 | – | 0.155 | 0.567 |
| Bosentan + Tadalafil | 0.809 | – | 0.599 | 0.855 | – | 0.445 | – |
| Bosentan | 0.700 | 0.613 | 0.457 | 0.692 | 0.641 | 0.751 | 0.251 |
| Epoprostenol | 0.631 | 0.453 | – | – | 0.644 | – | – |
| Beraprost | 0.513 | 0.230 | 0.412 | – | 0.550 | – | 0.629 |
| Ambrisentan + Tadalafil | 0.426 | – | 0.757 | 0.563 | 0.632 | 0.043 | 0.587 |
| Riociguat | 0.409 | 0.435 | 0.328 | 0.216 | 0.522 | 0.596 | 0.589 |
| Selexipag | 0.397 | 0.638 | 0.387 | – | 0.225 | 0.669 | 0.609 |
| Macitentan | 0.303 | 0.609 | 0.246 | – | 0.252 | 0.807 | 0.336 |
| Treprostinil | 0.270 | 0.274 | 0.242 | 0.221 | 0.516 | 0.807 | 0.473 |
| Tadalafil | 0.177 | – | – | 0.513 | 0.420 | 0.259 | 0.750 |
| Ambrisentan | 0.142 | – | 0.604 | 0.225 | 0.787 | 0.196 | 0.789 |
| Placebo | 0.038 | 0.074 | 0.070 | 0.038 | 0.191 | 0.769 | 0.360 |
| Vardenafil | – | 0.549 | 0.749 | 0.806 | 0.872 | 0.364 | – |
| Bosentan + Epoprostenol | – | – | – | – | 0.253 | – | – |
The surface under the cumulative ranking curve (SUCRA) was used to calculate each intervention’s probability. The larger the SUCRA value, the better the rank of the intervention.
AE: adverse event; 6MWD: 6-minute walking distance; mPAP: mean pulmonary arterial pressure; WHO FC improvement: WHO functional class (FC) improvement; SAE: serious adverse events.